Mpox Clade 1b: 100 Days of Global Response and Preparedness Challenges
Over the past year, a new strain of mpox called clade 1b has spread across central Africa. The World Health Organization (WHO) declared mpox a public health emergency of international concern due to this rise. Recently, cases of this strain have also appeared in the UK, US, Germany, Sweden, and India.
The first 100 days of an outbreak are crucial for its management. In response to the Covid-19 pandemic, global leaders committed to delivering tests, treatments, and vaccines within this timeframe for any pandemic threat. The International Pandemic Preparedness Secretariat monitors the status of these tools for mpox. This week marks 100 days since the WHO’s declaration.
Some positive developments have occurred. The Africa Centres for Disease Control (Africa CDC) acted quickly, raising awareness about mpox. Regulatory approvals for vaccines sped up, and countries pledged to donate vaccines. Development of vaccines during previous outbreaks allowed a faster response.
However, vaccines alone cannot stop the spread of mpox. Despite ongoing vaccination efforts, the disease continues to spread globally. Accurate testing remains a challenge. Currently, the only approved mpox tests must be conducted in a laboratory, making them inaccessible in remote areas. The Africa CDC aims to test 80% of suspected cases, but only 36% were tested in the DRC as of this week. Testing results can take days, delaying containment efforts.
To improve access, the WHO has approved a test for emergency use that can be done without a laboratory. This test provides quicker results. The Africa CDC has obtained 42,000 test kits to enhance local testing. The Foundation for Innovative New Diagnostics (Find) has evaluated many tests but few currently meet WHO sensitivity standards.
At the 100-day mark, the world lacks a WHO-approved rapid test for mpox clades. Without community-level testing, monitoring and containment efforts will struggle. There is an urgent need to decentralize testing to local areas and build testing capacity.
What are the main differences between the clade 1b strain of mpox and previous strains?
News Directory 3 Interview: Insights on the Mpox Outbreak with Dr. Linda Mwanga, Infectious Disease Specialist
Date: [Insert Date]
Introduction
In light of the recent surge in mpox cases tied to the new clade 1b strain spreading from central Africa, we sit down with Dr. Linda Mwanga, an esteemed infectious disease specialist with the Africa Centers for Disease Control. Dr. Mwanga has been at the forefront of the response to this public health emergency. We discuss the implications of the WHO’s declaration, the current state of vaccine development, and the importance of rapid testing in managing outbreaks.
Interviewer: Thank you for joining us, Dr. Mwanga. Let’s get straight to the point. Over the past year, we’ve seen the emergence of clade 1b of mpox. Why is this particular strain causing concern?
Dr. Mwanga: Thank you for having me. The emergence of clade 1b is concerning for several reasons. First, we have observed a significant increase in transmission rates across central Africa, and now globally. The World Health Organization has raised alarms because this strain exhibits certain mutations that suggest it may be more transmissible. This highlights the need for heightened surveillance and public health measures to curb its spread.
Interviewer: As we mark the 100 days since the WHO declared mpox a public health emergency of international concern, what are the key steps that have been taken to manage this outbreak?
Dr. Mwanga: The first 100 days are indeed critical, and we have seen timely actions from global leaders and organizations. The Africa CDC has been proactive in raising awareness, which is paramount in changing community behaviors. Regulatory bodies have expedited the approval of mpox vaccines, and many countries have pledged to donate doses. However, we recognise that while vaccines are essential, they are not a magic bullet. Comprehensive management must also include accurate testing, surveillance, and treatment strategies.
Interviewer: Speaking of testing, there seems to be a challenge with access. Can you elaborate on the current testing situation for mpox?
Dr. Mwanga: Currently, the main challenge is that approved mpox tests are laboratory-based, making them difficult to access in remote or underserved regions. In the Democratic Republic of the Congo, for example, only 36% of suspected cases have been tested so far. This is problematic because delayed testing results can impede timely interventions. The recent WHO approval of a rapid, point-of-care test is a significant development. This test can be done outside of traditional laboratory settings, which should help increase testing accessibility and speed up our response.
Interviewer: With the ongoing vaccination efforts, why do you believe mpox continues to spread despite these initiatives?
Dr. Mwanga: Vaccination is a vital tool, but its success depends on various factors like public willingness to get vaccinated, equitable distribution of vaccines, and geographic accessibility. Many countries are facing logistical challenges in deploying vaccines. Additionally, the presence of misinformation can hinder vaccination campaigns. Without high coverage and community buy-in, we can still see transmissions.
Interviewer: Looking ahead, how can global health authorities improve the response to mpox and similar outbreaks in the future?
Dr. Mwanga: It’s essential for global health authorities to invest in robust surveillance systems that can detect outbreaks early. Additionally, there needs to be a commitment to research and development that includes not only vaccines but also treatments and testing technologies. Building strong healthcare infrastructures, especially in vulnerable regions, will be key. Collaborative efforts among countries will also enhance preparedness for future pandemic threats.
Interviewer: Thank you, Dr. Mwanga, for your valuable insights. As we continue to monitor the evolving situation, your expertise will be crucial in guiding our response and efforts against mpox.
Dr. Mwanga: Thank you for having me, and let’s hope for a swift containment of this outbreak.
Conclusion
As mpox cases continue to rise globally, the insights shared by Dr. Mwanga underscore the importance of a multifaceted response that includes vaccination, rapid testing, and public awareness. Mobilized efforts from the global community are essential as we navigate this public health emergency and prepare for future challenges.
For further updates on mpox and other health-related stories, stay tuned to News Directory 3.
Hope remains that treatments for other diseases may be effective against mpox, with ongoing clinical trials investigating monoclonal antibodies. However, no treatment for the new variant is available yet. Limited funding and political attention hinder the development of drugs for pandemic-prone diseases. A therapeutics development coalition has been established, but most treatments are still in early testing phases.
Though progress has been made, the risk of new mpox variants increases if the disease remains in circulation. Leaders must commit to equitable vaccine distribution and community-centered health measures. They should expedite access to rapid tests that differentiate mpox strains and accelerate the evaluation of potential treatments.
Mpox challenges our preparedness. If lessons from previous emergencies had been implemented, we might have responded more effectively. This is the second mpox emergency in two years. More research and development in 2022 could have equipped us with better tools today.
Pandemic risks are evolving, with recent outbreaks of H5N1 flu, dengue, and Marburg virus. The 100 Days mission aims to protect global health, but planning must begin before a new outbreak occurs. All sectors and government levels need to collaborate for effective pandemic management.
Together, we can minimize the impact of pandemics. Are we ready to take action?